Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 05, 2025, titled "Zydus receives final approval from USFDA for Dasatinib Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg".
Press Release Mar 05 2025
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has received final approval from the USFDA for Dasatinib Tablets in various strengths. Dasatinib is used for treating specific types of leukemia in adults. The tablets will be manufactured at Zydus Lifesciences' facility in Ahmedabad.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Mar 04 2025
- Press Release Feb 26 2025
- Press Release Feb 22 2025
- Press Release Feb 14 2025
- Press Release Feb 12 2025
Later from Zydus Lifesciences
- Press Release Mar 10 2025
- Press Release Mar 12 2025
- Press Release Mar 14 2025
- Press Release Mar 16 2025
- Press Release Mar 18 2025
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences